|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of circulating monocyte markers in malignant histiocytosis suggests that this tumor originates in monocytes or free histiocytes, whereas the phenotype of true histiocytic lymphoma is compatible with an origin in fixed histiocytes, which generally are devoid of the monocyte markers CD11b and CD14.
|
1647137 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, it was shown that Oncoimmunin-M (OI-M), a recently identified tumor cell-derived 36 kDa protein, is able both to inhibit the proliferation of the human promyelocytic leukemic cell line HL-60 while maintaining viability in culture and to induce a bimodal distribution of CD11b, the alpha chain of the integrin MAC-1, on the cell surface (Packard, B.Z. and Komoriya, A.(1993) J. Biol.Chem.268, 6356-6363).
|
8031851 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Histological examination revealed infiltration of monocytic cells into the tumor of GM-CSF-producing cells, and they were shown to be mainly CD11b positive cells by immunohistochemical staining.
|
9568072 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Depletion of AML1/MTG8 correlates with an increased susceptibility of both Kasumi-1 and SKNO-1 cells to tumor growth factor beta(1) (TGF beta(1))/vitamin D(3)-induced differentiation, leading to increased expression of CD11b, macrophage colony-stimulating factor (M-CSF) receptor, and C/EBP alpha (CAAT/enhancer binding protein).
|
12480707 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Between 13 and 23% of primary human CD3+, CD4+, CD8+, CD11b+, and CD19+ cells and more than 70% of CD4+ MT4 cells or various human tumor cell lines (MeWo, Huh7, HeLa, 293T, or H1299) could be transduced with one infectious unit of EHV-1 per cell.
|
15827159 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gemcitabine treatment attenuated the tumor-suppressive environment by eliminating CD11b(+)/Gr-1(+) myeloid-derived suppressor cells.
|
17671218 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The subpopulation of CD11b+/CD14⁻ cells in PBMNC was decreased in the advanced-stage NSCLC patients who had responsiveness to chemotherapy (n = 41, P < 0.0001) and in the early-stage NSCLC patients after removal of tumor (n = 8, P = 0.0391).
|
19572148 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DC.mTbet-based therapy also promoted superior tumor-specific Tc1 responses in the spleens and tumor-draining lymph nodes of treated animals, and within the tumor microenvironment it inhibited the accumulation of CD11b(+)Gr1(+) myeloid-derived suppressor cells and normalized CD31(+) vascular structures.
|
20675595 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ang2 protein levels were reduced by approximately 50% inside tumors (P < 0.01), whereas tumor microvessel density (P < 0.01) and intratumor proangiogenic Tie2(+)CD11b(+) cells (P < 0.05) were significantly reduced.
|
21233403 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Intravenous injection of MSCs carrying Adv-Stat3(-) suppressed the Stat3 pathway, down-regulated Ki67 expression, and recruited CD11b-positive cells in the local tumor, inhibiting tumor growth and increasing the survival of tumor-bearing mice.
|
22054049 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mice lacking S100A9 showed significantly reduced tumor incidence, growth and metastasis, reduced chemokine levels, and reduced infiltration of CD11b(+)Gr1(+) cells within tumors and premetastatic organs.
|
21228116 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, Gr1(+)CD11b(+) myeloid-derived suppressor cells (MDSCs), known to inhibit tumor reactive T cells, were enriched in melanoma lesions and lymphatic organs during tumor progression.
|
21969559 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using an in vivo model of tumor immunity, we show here that CD11b(hi)CD27(low) NK cells migrate to the tumor site to reject major histocompatibility complex class I negative tumors, a response that is severely impaired in Txb21(-/-) mice.
|
21389319 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Periodic acid-Schiff loops and CD11b⁺ macrophages within the tumor stroma decreased in vivo; CD31⁺ blood vessels were not altered.
|
21519029 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This reduction in tumor growth was associated with decreased formation of CD31(+) blood vessels and reduced infiltration of CD11b(+) macrophage linage cells into tumor tissues.
|
22143793 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CXCL1/2 attract CD11b(+)Gr1(+) myeloid cells into the tumor, which produce chemokines including S100A8/9 that enhance cancer cell survival.
|
22770218 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Phenotypic analysis revealed an increase in myeloid-derived suppressor cell (MDSC) cells (CD11b+ and Gr-1+) that coexpressed vascular-endothelial-growth factor receptor 1 (VEGF-R1) and elevated MMP activation present in tumors and spleens from timp2-/- mice.
|
22735808 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, abrogation of tumor-derived GM-CSF inhibited the recruitment of Gr-1(+) CD11b(+) cells to the tumor microenvironment and blocked tumor development-a finding that was dependent on CD8(+) T cells.
|
22698406 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-bearing mice with high C5a-producing syngeneic lymphoma cells had significantly accelerated tumor progression with more Gr-1+CD11b+ myeloid cells in the spleen and overall decreased CD4+ and CD8+ T cells in the tumor, tumor-draining lymph nodes, and the spleen.
|
22914051 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, a G-CSF independent downregulation of Bv8 was found as a common target of all three DmiRs and correlated with decreased tumor recruitment of bone marrow-derived CD11b+ Gr-1+ myeloid cells.
|
22952847 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data showed that CXCL17-expressing tumor cells increased immature CD11b(+)Gr1(+) myeloid-derived cells at tumor sites in mice and promoted CD31(+) tumor angiogenesis.
|
22952881 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In patients with colorectal cancer, the presence of circulating CD11b(+)Jag2(+) cells was accompanied by loss of E-cadherin in the corresponding patient tumors.
|
23722542 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, Sox17 increased the percentage of tumor-associated CD11b+Gr-1+ myeloid cells within tumors.
|
23241958 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-derived IL-35 increases CD11b(+)Gr1(+) myeloid cell accumulation in the tumor microenvironment and, thereby, promotes tumor angiogenesis.
|
23345334 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The absence of hematopoietic CCL5 causes aberrant generation of CD11b(+)/Gr-1(+), myeloid-derived suppressor cells (MDSCs) in the bone marrow in response to tumor growth by accumulating Ly6C(hi) and Ly6G(+) MDSCs with impaired capacity to suppress cytotoxicity of CD8(+) T cells.
|
23266888 |
2013 |